Healthcare Leadership Council

02/15/2024

The Healthcare Leadership Council is asking the Biden Administration to withdraw proposed regulatory guidance that could create a “march-in” process for the federal government to override a company’s intellectual property rights, ultimately reducing the flow of new treatments and cures for American patients.

Read more: https://www.hlc.org/news/healthcare-leadership-council-urges-biden-administration-to-withdraw-guidance-on-march-in-rights-to-preserve-medical-progress-prevent-cost-increases/

12/19/2023

Report by Avalere finds the proposal to “stack” drug discounts in calculating Medicaid best price could lead to disruption for patients, pharmacies, payers, and manufacturers.

Learn more:
https://www.hlc.org/news/analysis-proposed-change-in-medicaid-drug-rebate-program-could-affect-drug-pricing-access-in-other-markets/

12/12/2023

The Healthcare Leadership Council has named Business Roundtable's Maria Ghazal as President and CEO, and Johnson & Johnson's Calvin W. Schmidt as 2024-2025 Chairman of the Board. Full release: https://www.hlc.org/news/healthcare-leadership-council-names-new-president-ceo-and-chairman-of-the-board-to-chart-future-of-patient-centered-advocacy/

11/03/2023

The Healthcare Leadership Council and Confidentiality Coalition brought together an expert panel for a congressional briefing to discuss opportunities for artificial intelligence in healthcare. The panel consisted of representatives from EMDgroup, Marshfield Clinic Health System, The Mount Sinai Hospital, NewYork-Presbyterian Hospital, Oracle, and Premier Inc.. The discussion revolved around how to gain trust through protecting data privacy, and how to utilize this tool to reduce healthcare worker burnout and improve the delivery of care.

10/26/2023

Journalists should help explain ‘the why’ behind the problems within caregiving, says The Wall Street Journal’s Clare Ansberry. Then, policy can help, Healthcare Leadership Council’s Executive Vice President and COO Debbie Witchey says.

10/18/2023

There are a couple of important takeaways from CBO's recent report that can enhance CMMI’s work and lead to more successes moving forward.

Learn more: https://www.hlc.org/post/the-cbo-report-and-lessons-for-cmmis-future/

09/14/2023

Many seniors fear price controls will limit access to newer prescription drugs in addition to the drugs they currently use. HLC president Mary R. Grealy discusses lack of senior support for IRA implementation in a Real Clear Health op-ed.

Medicare’s recent announcement of the ten prescription medications that will be subject to government price controls, under the provisions of the Inflation Reduction Act, provides an opportune j

08/30/2023

New Morning Consult survey shows that over 90 percent of American seniors like their Medicare Part D drug program. Beneficiaries say their drug coverage is affordable and provides good value. As the federal government announces the first list of prescription drugs to be subject to government price controls, it’s important to ask if this is what seniors want? The survey shows two-thirds of seniors want prices negotiated by private plans and pharmaceutical companies, with only 16 percent preferring government-controlled pricing and availability.

Release: https://www.hlc.org/news/over-90-percent-of-american-seniors-satisfied-with-their-medicare-prescription-drug-coverage-new-survey-shows/